Australia's Cynata Therapeutics leaps as clinical trial progresses

Cynata Therapeutics' shares rose as much as 7.6% after announcing 65 patients have been enrolled in its Phase 2 clinical trial of CYP-001 for acute graft versus host disease (aGvHD). CYP-001 is designed to modulate the immune system and improve response rates and survival outcomes in aGvHD, a life-threatening complication.